{"id":"at1-blocker-candesartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan is an angiotensin II receptor antagonist that selectively binds to AT1 receptors on vascular smooth muscle and other tissues, blocking the effects of angiotensin II. This prevents vasoconstriction, reduces aldosterone secretion, and decreases sodium reabsorption, leading to vasodilation and blood pressure reduction. In the context of The Netherlands Cancer Institute's phase 3 trial, AT1 blockade may be investigated for potential anti-angiogenic or immunomodulatory effects in cancer treatment.","oneSentence":"Candesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:52.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute)"}]},"trialDetails":[{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT00459771","phase":"PHASE3","title":"Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2007-06","conditions":"Breast Cancer","enrollment":210},{"nctId":"NCT01444833","phase":"NA","title":"Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker","status":"UNKNOWN","sponsor":"Slovak Academy of Sciences","startDate":"2008-10","conditions":"Hypertension","enrollment":35},{"nctId":"NCT00310778","phase":"PHASE1","title":"Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-03","conditions":"Healthy","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AT1 blocker candesartan","genericName":"AT1 blocker candesartan","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}